Skip to main content
. Author manuscript; available in PMC: 2013 Aug 14.
Published in final edited form as: Vaccine. 2008 Jul 23;26(31):3947–3957. doi: 10.1016/j.vaccine.2007.12.060

Table 1.

Study design of DP6-001 clinical trial

Group DNA prime phase
Protein boost phase
Plasmids (6) Dose (mg) Route Time (weeks) Proteins (5) Dose (mg) Route Time (weeks)
A (n = 10) gp120 (A, B, Bal, C, E) + Gag (C) 1.2 ID 0, 4, 12 gp120 (A, B, Bal, C, E) 0.375 IM 20, 28
B (n = 11) gp120 (A, B, Bal, C, E) + Gag (C) 1.2 IM 0, 4, 12 gp120 (A, B, Bal, C, E) 0.375 IM 20, 28
C (n = 6) gp120 (A, B, Bal, C, E) + Gag (C) 7.2 IM 0, 4, 12 gp120 (A, B, Bal, C, E) 0.375 IM 20

HIV-1 viral strains (GeneBank accession number) used for DNA or protein vaccines. (A) 92UG037.8 (U09127), (B) 92US715.6 (U08451), Bal: Ba-L (M68893), (C) 96ZM651 (AF286224), (E) 93TH976.17 (U08458).